Newsoara Biopharma

Privately held: no public share price · China

Assets

(3 total)
3Total Assets
1Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Bexagliflozin(Brenzavvy)
Approved
SGLT2Small molecule
Type 2 Diabetes
Phase 3
PDE4Small molecule
Psoriasis
Phase 1
Undisclosed / early pipelineSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 October 2026Topline resultHPP737Prifemilast Phase 3 head-to-head vs apremilast (NCT07712731) met both co-primary endpoints
China · cAMPfield Therapeutics (Newsoara's ex-Greater China licensee) · Source ↗
1 April 2024Topline resultTHR-1442Phase 3 NCT05159882 published: bexagliflozin (THR-1442) noninferior to dapagliflozin on HbA1c at week 24
CN · Newsoara Biopharma Co., Ltd. (with TheracosBio authors) · Source ↗

Financial reports

No financial reports recorded.